During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer compared to the previous year, and prescription rates for the two drugs fell less than three percent overall—and 15.1 percent at the peak—according to an analysis published this week in the Journal of the National Cancer Institute by researchers from the University of Pennsylvania’s Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center…
